DB06058InvestigationalSmall molecule
XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. It is being developed to prevent HCV re-infection following...
- Mechanism
- Curator reviewed
XTL-6865 is a dual-antibody (Ab68 and Ab65) therapy directed against the highly mutagenic hepatitis C E2 envelope protein and intended therefore to inhibit viral entry into host cells.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C).Curator reviewed
- Code names
- XTL-6865
Resolves to
Targets
What you can answer from here — as of April 23, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with XTL-6865, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account